Scinai Immunotherapeutics SCNI 2026 Q2财报电话会议纪要

发布时间：2026-08-27 一、AI总结内容 一、核心要点 1. 公司当前已转型为兼具免疫肿瘤研发与双位点CDMO业务的平台型企业，2026年第二季度营收约94.9万美元，上半年运营亏损约460万美元，拥有现金及受限现金约285万美元。 2. 2026年CDMO业务目标营收约500万美元，截至8月16日签署的客户订单约310万美元，其中210万美元已开票。 3. 研发端聚焦优先级排序与资本纪律，优先推进高价值项目，寻求非稀释性资金、合作，减少股东稀释，核心项目包括与Pinto合作的PC111。 4. 2027年初公司目标为：商业端实现客户承诺转化为收入、提升产能利用率、获得重复业务；研发端明确最高优先级项目的里程碑，让市场更清晰公司定位。二、风险与关注 1. CDMO业务营收存在不确定性，需依赖客户项目执行和收入确认条件，无法直接由客户订单推算营收。2. 扩展的CDMO平台固定成本较高，需提升产能利用率以改善盈利状况。3. 外部融资工具（如CEPA）仅为备选，公司需谨慎运用，且新股权发行存在稀释可能性。 三、后续关注点 1. 2026年下半年商业执行成果，包括客户承诺转化为收入、产能利用率提升、重复业务拓展。2. 研发项目里程碑进展及资本运用效率。3. 非稀释性资金获取与融资结构优化。 二、音频原文（转写） So, on the R and D side, our focus is increasingly on prioritization and capital discipline. Wecontinue to to believe that our nano platform can support differentiated therapeutic formats, but we are being very deliberate about where we allocate capital. For each program, we are lookingnot only at the science, but also at the intended product profile, development's feasibility, differentiation, Technical risk and the financingrequired to reach the next meaningful value inflection point. We therefore intend to use non dilutive funding, collaborations and strategic partnerships whenever possible, rather than askingshareholders to finance every stage of development internally. PC 111 remains an important programme for us and is being advanced under our opti on agreement with Pinto. We believe it addressesserious determinants in their methodology. andconditions. with significant medical need But weare also maintaining a disciplined approach. tohave And when we deploy capital toward the program. YEAH very smart. I think there's a lot of excitement with a few different assets within thepipeline. So I would definitely encourage folksto check those out. 嗯。 Great. And I think we hit on a lot of the core takeaways from the reports. So I'd encourage people to continue submitting questions. As we get close to wrapping up here, I have one more question for him here, but then we'll jump into the audience Q&A. But before we wrap up here, I thinka good place to leave on is. If we're having this conversation again at the beginning of 2027, so looking several months down the road, what would you like to have accomplished between now andthen, right? What should investors be looking out for from anexecution story?So exactly tapping into the last word you just said, I would like investors tobe able to look back. at the second half of 2026, can see measurable execution. on the commercial side. I would like to see customer commitmentstranslated into work and revenue. additional customers coming onto the platform higher utilization of our capacity across Jerusalem and Yabnehand evidence of repeat business. on the r and dside. I would like us to have. I plan. our highest priority programs 猪。 clearly defined milestones. While maintaining the capital discipline. Have established. and It incorporates wisdom. I would like the market to have a much clearer understanding of what Sinai has become. We are building a company that combines innovative immunology R&D. with real pharmace utical development and manufacturing capabilities. So when we speak again in early twenty seven.I want to be talking less about. What we intendto build. and much more about what we have demonstrated. revenues generated. customers added utilization increased are indeed milestones achieved. and capital deployed intelligence fantasticThank you, thank you. That's quite helpful. So perfect. Now, now I'd like to take some time to jump into some audience questions. So I'll give,I see one or two coming in here. I'll give, I'llgive everyone another kind of call, fifteen, twenty seconds to submit some additional questions. And what I'll just add at the end here is I think Sinai represents a really unique opportunity, right? Not only has this growing CDMO platform that isclearly getting more customer accounts, but thenthere's the excitement between behind this R and D pipeline, which On the earlier side, it's still very exciting with some of the assets that you have acquired and are focused on developing.And In spaces that we're seeing continued interest and support. just across the sector. So I think it's really exciting time for for Sinai as well, you know, as a platform at this stage and. excited to see what the rest of this year and kind of early twenty twenty seven looks like. 啊 With that said, I see a couple of questions comingin here on both platforms. So let me just pull those up. And I think we have time for a couple.So this was the first one I saw. So we'll starthere. Um Okay. So this one has to do with kind of the SEPA that your team has in place in here.But Uh, the question says i saw that sinai is updating the f one registration statement coveringthe fifteen million dollars cap up. Should shareholders expect 15 million dollars of dilution in the near term? Absolutely not. defining update the registrationspin print that we already have. Underlying ourexisting setup. to reflect our june th